On a roll, Rigel flags a positive PhII for its lead, late-stage drug fostamatinib
Rigel has been having one of those weeks its investors have been dreaming of for years.
First the biotech $RIGL, which has had some mixed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
